OSCR

TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activated Immunosuppression in Diffuse Glioma: A Multi-Cohort Transcriptomic Study.

Overview

Authors: Ehab Balawi1,2, Zhicheng Jiang2,3, Xianwei Wang2,3, Dong Chen1,2,3
  1. Graduate School, Dalian Medical University, Dalian 116044, China
  2. Department of Neurosurgery, Dalian Municipal Central Hospital, Dalian 116033, China; (Z.J.)
  3. Faculty of Medicine, Dalian University of Technology, Dalian 116024, China
Journal: Cancers, volume 18, issue 13, article 2092
Dates: received 25 May 2026; accepted 23 June 2026; published online 27 June 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.3390/cancers18132092 · PMID 42449636 · PMCID PMC13359701 · OpenAlex W7166440498
Open access: gold, a free copy (OpenAlex)
Status: code on request (how the code is found and verified)
Categories: genetics / omics (modality), human (organism), other condition (population)
Methods: Statistics, Smoothing, state filtering, decompositions, Connectivity
Keywords: TGFB2, diffuse glioma, microglia, immune checkpoint, immune evasion, tumor microenvironment
Topic: Glioma Diagnosis and Treatment (Oncology, Medicine), according to OpenAlex
Funding: Dalian University of Technology (2025SZ021 & 2025SZ022)
Citations: not cited yet (Europe PMC); 80 references in the paper

Abstract

Background/Objectives: TGFB2 is the dominant TGF-β isoform in glioma, and isolated experimental studies have implicated it in immunosuppressive signaling; however, its prognostic value and systematic association with the tumor immune microenvironment across the diffuse glioma spectrum have not been comprehensively characterized in large clinical cohorts. Methods: A multi-cohort transcriptomic study was conducted using TCGA (n = 667) as discovery and CGGA (n = 404) as validation, integrating survival analysis, functional enrichment, immune deconvolution by ssGSEA and MCP-counter, immune checkpoint correlation, and TISCH2-based single-cell localization. Results: TGFB2 was consistently overexpressed in glioma relative to normal brain at both mRNA and protein levels, with expression highest in GBM (median 10.60 vs. 8.45 in LGG; p < 2.2 × 10−16) and increasing across WHO grade. High TGFB2 predicted worse overall survival in both cohorts (TCGA: 648 vs. 2907 days; CGGA: 863 vs. 3107 days; both p < 0.0001), with 3-year AUCs of 0.823 and 0.714, and retained independent prognostic significance in the CGGA multivariate model (HR = 1.343; p = 3.2 × 10−4). Hallmark GSEA identified consistent enrichment of interferon signaling, epithelial–mesenchymal transition, TNFα/NF-κB, and IL-6/JAK/STAT3 pathways. ssGSEA and MCP-counter concordantly demonstrated significantly expanded myeloid, monocytic, and stromal populations across both cohorts. TGFB2 correlated positively with PD-L1, TIM-3, ICOS (ρ = 0.449), IL2RA (ρ = 0.397), CTLA4 (ρ = 0.375), and TIGIT (ρ = 0.170) in TCGA, with all associations replicated in CGGA. Conclusions: TGFB2 is an adverse prognostic biomarker in diffuse glioma coupled to a myeloid-enriched, multi-checkpoint-activated tumor microenvironment, supporting its evaluation as a stratification biomarker in TGF-β/checkpoint combination immunotherapy trials.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.

The paper's code and data availability statement is in the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.

Data

Datasets cited

Data Availability Statement

The raw data supporting the findings of this study are publicly available from the following repositories: TCGA RNA-seq expression and clinical data were downloaded from the Genomic Data Commons (GDC) portal (https://gdc.cancer.gov/). Molecular annotation for TCGA samples was obtained from cBioPortal PanCancer Atlas (https://www.cbioportal.org/). CGGA RNA-seq (mRNAseq_693) expression and clinical data were downloaded from the CGGA portal (https://www.cgga.org.cn/). Single-cell RNA-seq data were accessed through TISCH2 (https://tisch.compbio.cn/). Protein-level expression data were accessed through UALCAN (https://ualcan.path.uab.edu). Processed results supporting all figures and conclusions are provided as Supplementary Tables S1–S5 and Supplementary Figures S1–S6. Additional data tables and all R analysis scripts are available from the corresponding author upon reasonable request.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 4 authors, 6 keywords, 1 funder, 75 references.

Cite

This paper

Balawi, E., Jiang, Z., Wang, X., & Chen, D. (2026). TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activated Immunosuppression in Diffuse Glioma: A Multi-Cohort Transcriptomic Study. Cancers, 18(13), 2092. https://doi.org/10.3390/cancers18132092

BibTeX

@article{balawi2026tgfb2,
author = {Balawi, Ehab and Jiang, Zhicheng and Wang, Xianwei and Chen, Dong},
title = {{TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activated Immunosuppression in Diffuse Glioma: A Multi-Cohort Transcriptomic Study}},
journal = {Cancers},
year = {2026},
month = jun,
volume = {18},
number = {13},
pages = {2092},
publisher = {Multidisciplinary Digital Publishing Institute (MDPI)},
issn = {2072-6694},
doi = {10.3390/cancers18132092},
url = {https://doi.org/10.3390/cancers18132092},
pmid = {42449636},
pmcid = {PMC13359701}
}

RIS

TY - JOUR
AU - Balawi, Ehab
AU - Jiang, Zhicheng
AU - Wang, Xianwei
AU - Chen, Dong
TI - TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activated Immunosuppression in Diffuse Glioma: A Multi-Cohort Transcriptomic Study
T2 - Cancers
J2 - Cancers (Basel)
PY - 2026
DA - 2026/06/27
VL - 18
IS - 13
SP - 2092
SN - 2072-6694
PB - Multidisciplinary Digital Publishing Institute (MDPI)
DO - 10.3390/cancers18132092
UR - https://doi.org/10.3390/cancers18132092
LA - en
ER -

CSL-JSON

{
"id": "10.3390/cancers18132092",
"type": "article-journal",
"title": "TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activated Immunosuppression in Diffuse Glioma: A Multi-Cohort Transcriptomic Study",
"container-title": "Cancers",
"author": [
{
"family": "Balawi",
"given": "Ehab"
},
{
"family": "Jiang",
"given": "Zhicheng"
},
{
"family": "Wang",
"given": "Xianwei"
},
{
"family": "Chen",
"given": "Dong"
}
],
"container-title-short": "Cancers (Basel)",
"volume": "18",
"issue": "13",
"page": "2092",
"DOI": "10.3390/cancers18132092",
"PMID": "42449636",
"PMCID": "PMC13359701",
"ISSN": "2072-6694",
"publisher": "Multidisciplinary Digital Publishing Institute (MDPI)",
"URL": "https://doi.org/10.3390/cancers18132092",
"language": "en",
"issued": {
"date-parts": [
[
2026,
6,
27
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1371/journal.pone.0295346
Integrated bioinformatics analysis and experimental validation identified CDCA families as prognostic biomarkers and sensitive indicators for rapamycin treatment of glioma.
Journal: PloS one
In common: other condition, 10 references
[2] doi:10.3390/biomedicines13112640 [code]
A Prognostic Neuromodulation-Related Gene Signature Identifies Immunomodulation and Tumour-Associated Hallmarks in Glioblastoma.
Journal: Biomedicines
In common: other condition, 9 references
[3] doi:10.1038/s41698-025-01260-6 [code]
A machine learning-defined cellular senescence signature systematically enhances prognostication and guides immunotherapy strategies for the treatment of gliomas.
Journal: NPJ precision oncology
In common: other condition, 10 references
[4] doi:10.1038/s41420-022-00883-z
Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) expression in glioblastoma is driven by ETS1- and MYBL2-dependent transcriptional activation.
Journal: Cell death discovery
In common: other condition, 9 references
[5] doi:10.1080/07853890.2024.2405079
Necroptosis-based glioblastoma prognostic subtypes: implications for TME remodeling and therapy response.
Journal: Annals of medicine
In common: NCBI GEO GSE148842, other condition, 4 references
[6] doi:10.1016/j.isci.2022.105276 [code]
Integrative genomic analysis facilitates precision strategies for glioblastoma treatment.
Journal: iScience
In common: other condition, 9 references
[7] doi:10.1186/s40478-023-01651-5
Translocator protein (18kDA) (TSPO) marks mesenchymal glioblastoma cell populations characterized by elevated numbers of tumor-associated macrophages.
Journal: Acta neuropathologica communications
In common: genetics / omics, other condition, 8 references
[8] doi:10.3389/fimmu.2026.1752553
Metabolic reprogramming of glioma-associated macrophages identifies detoxification and energetic macrophages as drivers of immunosuppression and therapeutic vulnerability.
Journal: Frontiers in immunology
In common: genetics / omics, other condition, 7 references
[9] doi:10.3390/biology12050648 [code]
Identification of Prominent Genes between 3D Glioblastoma Models and Clinical Samples via GEO/TCGA/CGGA Data Analysis.
Journal: Biology
In common: other condition, 7 references
[10] doi:10.1016/j.ebiom.2022.104239
Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM.
Journal: EBioMedicine
In common: genetics / omics, other condition, 7 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.